VANCOUVER, British Columbia, Sept. 26, 2019 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis producers, is pleased to announce that its research partner, McGill University, has received a license from Health Canada which allows for the possession and production of cannabis for research purposes.
The license allows RavenQuest and McGill to continue important research around the cannabis plant.  The research continues to focus on cultivar recognition, plant stabilization, yield maximization and disease resistance of the cannabis plant. RavenQuest CEO, George Robinson, commented that “throughout our partnership with McGill, research has thus far uncovered several key beneficial microbes which have shown significant potential to improve yield and disease resistance.  The Health Canada license will allow RavenQuest and McGill to confirm our findings by applying the microbes directly to the cannabis plant.”“RavenQuest’s foundation is grounded in science and innovation. As a company, we have always maintained that large scale Cannabis producers need to develop non-GMO methods to produce genetically consistent, disease resistant and biologically stable plant material that will meet pharmaceutical standards for clinicians to conduct medical research trials.  With the granting of this license, the research we are conducting with our partners at McGill moves us even closer toward that end,” Robinson continued.For more information, access RavenQuest’s investor presentation, fact sheet and videos here.Follow RavenQuest:Twitter:
https://twitter.com/RQBGlobalInstagram: 
https://www.instagram.com/ravenquestbm/Facebook:
https://www.facebook.com/RavenQuest-BioMed-2355335751374131/?view_public_for=2355335751374131LinkedIn:
https://www.linkedin.com/company/ravenquest-biomedAbout RavenQuest BioMed Inc.RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.“George Robinson”
Chief Executive OfficerFor further information, please contact: Mathieu McDonald, Corporate Communications
1-877-282-1586Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.Cautionary Note Regarding Forward-Looking StatementsAll statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. Examples of such statements include statements with respect to the construction of cannabis facilities in Europe and the cannabis production capacity and location of such facilities, the name of the joint venture and the funding of the Joint Venture by the Company’s Joint Venture partner (which is under no obligation to provide funding). The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Bay Street News